Table of Contents Author Guidelines Submit a Manuscript
Journal of Tropical Medicine
Volume 2009 (2009), Article ID 781865, 7 pages
http://dx.doi.org/10.1155/2009/781865
Clinical Study

Efficacy of Artesunate + Sulphadoxine-Pyrimethamine (AS + SP) and Amodiaquine + Sulphadoxine-Pyrimethamine (AQ + SP) for Uncomplicated falciparum Malaria in Equatorial Guinea (Central Africa)

1Centre for the Control of Diseases, Reference Laboratory of Malaria, National Centre of Tropical Medicine—ISCIII, Malabo, Equatorial Guinea
2National Centre of Tropical Medicine, Institute of Health Carlos III, 28029 Madrid, Spain
3Reference Laboratory of Malaria, MINSABS and ISCIII, Malabo, Equatorial Guinea
4Reference Laboratory of Malaria, MINSABS and ISCIII, Bata, Equatorial Guinea
5Paediatric Department, Regional Hospital of Malabo, Malabo, Equatorial Guinea

Received 6 October 2008; Revised 11 February 2009; Accepted 26 March 2009

Academic Editor: Sukla Biswas

Copyright © 2009 Pilar Charle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “Africa Malaria Report,” World Health Organization, Geneva, Switzerland, 2003.
  2. WHO, “Drug Resistance in Malaria,” World Health Organization, Geneva, Switzerland, 2001.
  3. J. Roche, A. Guerra-Neira, J. Raso, and A. Benito, “Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea),” American Journal of Tropical Medicine and Hygiene, vol. 68, no. 5, pp. 598–601, 2003. View at Google Scholar
  4. WHO, “The African Summit on Roll Back Malaria,” Abuja, Nigeria, April 2000.
  5. WHO, “Antimalarial drug combination therapy,” World Health Organization Geneva, Switzerland, 2001.
  6. WHO, “Guidelines for the treatment of malaria,” (WHO/HTM/MAL/2006.1108), World Health Organization, Geneva, Switzerland, 2006.
  7. F. Robert, F. Ntoumi, G. Angel et al., “Extensive genetic diversity of Plasmodium falciparum isolates collected from patients with severe malaria in Dakar, Senegal,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 90, no. 6, pp. 704–711, 1996. View at Publisher · View at Google Scholar
  8. UNPD, “World Population Prospects: The 2006 Division,” United Nations Population Division.
  9. G. Pardo, M. A. Descalzo, L. Molina et al., “Impact of different strategies to control Plasmodium infection and anaemia on the island of Bioko (Equatorial Guinea),” Malaria Journal, vol. 5, article 10, pp. 1–8, 2006. View at Publisher · View at Google Scholar
  10. WHO, “Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria,” World Health Organization, Geneva, Switzerland, 2003.
  11. D. Schellenberg, E. Kahigwa, C. Drakeley et al., “The safety and efficacy of sulfadoxine-pyrimethamine, amodiaquine, and their combination in the treatment of uncomplicated Plasmodium falciparum malaria,” American Journal of Tropical Medicine and Hygiene, vol. 67, no. 1, pp. 17–23, 2002. View at Google Scholar
  12. L. von Seidlein, P. Milligan, M. Pinder et al., “Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial,” The Lancet, vol. 355, no. 9201, pp. 352–357, 2000. View at Publisher · View at Google Scholar
  13. M. Bonnet, C. Roper, M. Félix, L. Coulibaly, G. M. Kankolongo, and J. P. Guthmann, “Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré,” Malaria Journal, vol. 6, article 54, pp. 1–8, 2007. View at Publisher · View at Google Scholar
  14. P. A. Phillips-Howard and A. B. Bjorkman, “Ascertainment of risk of serious adverse reactions associated with chemoprophylactic antimalarial drugs,” Bulletin of the World Health Organization, vol. 68, no. 4, pp. 493–504, 1990. View at Google Scholar
  15. D. Ménard, N. N. H. Andrianina, Z. Ramiandrasoa et al., “Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar,” Malaria Journal, vol. 6, article 65, pp. 1–8, 2007. View at Publisher · View at Google Scholar
  16. G. Dorsey, S. Staedke, T. D. Clark et al., “Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial,” Journal of the American Medical Association, vol. 297, no. 20, pp. 2210–2219, 2007. View at Publisher · View at Google Scholar
  17. N. J. White, “Preventing antimalarial drug resistance,” Drug Resist Updates, vol. 1, no. 1, pp. 3–9, 1998. View at Publisher · View at Google Scholar
  18. T. K. Mutabingwa, D. Anthony, A. Heller et al., “Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial,” The Lancet, vol. 365, no. 9469, pp. 1474–1480, 2005. View at Publisher · View at Google Scholar
  19. J. M. Mwangi, S. A. Omar, and L. C. Ranford-Cartwright, “Comparison of microsatellite and antigen-coding loci for differentiating recrudescing Plasmodium falciparum infections from reinfections in Kenya,” International Journal for Parasitology, vol. 36, no. 3, pp. 329–336, 2006. View at Publisher · View at Google Scholar